Premium
Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin
Author(s) -
Takano Masashi,
Ikeda Yuji,
Kudoh Kazuya,
Kita Tsunekazu,
Sasaki Naoki,
Kikuchi Yoshihiro
Publication year - 2013
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2012.02047.x
Subject(s) - medicine , oxaliplatin , trabectedin , bevacizumab , refractory (planetary science) , oncology , ovarian cancer , chemotherapy , ovarian carcinoma , ovary , clear cell carcinoma , carcinoma , surgery , cancer , colorectal cancer , soft tissue , physics , soft tissue sarcoma , astrobiology
Clear cell carcinoma of the ovary has shown an exceedingly chemo‐resistant phenotype, especially in cases that are recurrent or refractory to previous therapy. Also, progression‐free survival was less than 6 months, even in the patients that achieved response when they were treated with conventional anti‐cancer cytotoxic agents. We present a case with recurrent and refractory ovarian clear cell carcinoma that achieved complete remission using a combination of bevacizumab, trabectedin and oxaliplatin. The progression‐free interval of the patient is over 30 months, and she is still receiving the combination therapy without toxicities of more than grade 2.